ANDA 62233, held by Glaxosmithkline. Cloxacillin Sodium.
As of Nov 16, 2026, ANDA 62233 (Cloxapen), held by Glaxosmithkline, was not approved, with 0 approved supplements and 0 published complete response letters.
| CloxapenEQ 250MG BASE · capsule;oral | Cloxacillin Sodium | Discontinued |
| CloxapenEQ 500MG BASE · capsule;oral | Cloxacillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters